Wedbush Securities Inc. Decreases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Wedbush Securities Inc. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 8.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,233 shares of the company’s stock after selling 382 shares during the period. Wedbush Securities Inc.’s holdings in Moderna were worth $503,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Cedar Wealth Management LLC boosted its holdings in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares during the last quarter. Commerzbank Aktiengesellschaft FI boosted its stake in Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares during the last quarter. CVA Family Office LLC grew its position in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC increased its stake in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Moderna by 32.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after purchasing an additional 116 shares during the period. Institutional investors own 75.33% of the company’s stock.

Insider Activity

In other Moderna news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the transaction, the president now directly owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 689 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 108,158 shares of company stock worth $13,239,712. 15.70% of the stock is currently owned by insiders.

Moderna Price Performance

MRNA stock opened at $69.68 on Friday. The firm has a 50 day simple moving average of $96.06 and a two-hundred day simple moving average of $111.86. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The stock has a market cap of $26.78 billion, a PE ratio of -4.45 and a beta of 1.68. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the business earned ($3.62) earnings per share. The firm’s quarterly revenue was down 29.9% compared to the same quarter last year. On average, analysts predict that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of recent research reports. Royal Bank of Canada downgraded Moderna from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $125.00 to $90.00 in a research report on Monday, August 5th. Evercore ISI restated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. The Goldman Sachs Group cut their target price on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Barclays cut their price objective on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a report on Friday, August 2nd. Ten equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $123.79.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.